Get the Stockscreener App
9.655
0.47%
0.045
Amneal Pharmaceuticals Inc stock is traded at $9.655, with a volume of 100.02K.
It is up +0.47% in the last 24 hours and up +4.27% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$9.61
Open:
$9.64
24h Volume:
100.02K
Relative Volume:
0.06
Market Cap:
$3.03B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-14.19
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
-4.31%
1M Performance:
+4.27%
6M Performance:
+12.01%
1Y Performance:
+10.85%
1-Day Range:
$9.61
$9.715
1-Week Range:
$9.57
$10.11
52-Week Range:
$6.685
$10.34
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
9.655 | 3.02B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
147.55 | 65.12B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.66B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.2763 | 42.03B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.30 | 21.08B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.71 | 18.26B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Stop Loss: Is Amneal Pharmaceuticals Inc a potential multi baggerJuly 2025 Analyst Calls & High Accuracy Swing Trade Signals - خودرو بانک
FDA Accepts New Drug Application for Parkinson’s Disease Treatment - Docwire News
Excessive Daytime Sleepiness Pipeline Insight 2025: Amneal’s FDA Approval of Sodium Oxybate Oral Solution, Novel Orexin Agonists, and Next-Generation Sleep-Wake Modulators Redefine Narcolepsy Care | D - Barchart.com
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
JPMorgan Chase & Co. Boosts Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $14.00 - MarketBeat
Jones Financial Companies Lllp Takes $1.73 Million Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Caxton Associates LLP Buys New Stake in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Excessive Daytime Sleepiness Pipeline Insight 2025: Amneal's - openPR.com
Woodline Partners LP Has $12.60 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
AQR Capital Management LLC Boosts Holdings in AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
Is Amneal Pharmaceuticals Inc in a long term uptrend2025 Year in Review & Stepwise Entry and Exit Trade Signals - خودرو بانک
Acadian Asset Management LLC Has $21.76 Million Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Aug Rallies: Can Amneal Pharmaceuticals Inc continue delivering strong returns2025 Momentum Check & Target Return Focused Picks - خودرو بانک
Analyst Downgrade: What are the future prospects of Amneal Pharmaceuticals Inc2025 Key Highlights & Weekly High Momentum Picks - خودرو بانک
Aug Big Picture: Does Amneal Pharmaceuticals Inc. have pricing powerGap Up & Weekly Top Performers Watchlists - خودرو بانک
Goldman Sachs Group Inc. Has $7.85 Million Holdings in AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
Aug Final Week: Is Amneal Pharmaceuticals Inc stock undervalued right nowQuarterly Profit Summary & Daily Growth Stock Investment Tips - خودرو بانک
Nasdaq Moves: Is Amneal Pharmaceuticals Inc forming a double bottomQuarterly Trade Report & Long-Term Capital Growth Strategies - خودرو بانک
Amneal secures FDA approval for sodium oxybate solution - World Pharmaceutical Frontiers
Aug Outlook: Can Amneal Pharmaceuticals Inc continue delivering strong returnsWeekly Profit Recap & Consistent Profit Alerts - خودرو بانک
Portfolio Update: Can Amneal Pharmaceuticals Inc continue delivering strong returnsEarnings Overview Summary & Risk Controlled Swing Alerts - خودرو بانک
Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 52-Week HighShould You Buy? - MarketBeat
Amneal receives FDA approval of treatment for narcoleptic sufferers - ROI-NJ
Ophthalmic Packaging Market Worth USD 23.65 Billion by 2034 | Towards Packaging - GlobeNewswire Inc.
Ieq Capital LLC Takes $288,000 Position in AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
Why Amneal (AMRX) Stock Is Up Today - Yahoo Finance
Amneal wins FDA nod for generic targeting Jazz Pharma’s Xyrem - Seeking Alpha
Amneal Pharmaceuticals Wins US FDA Approval for Generic Version of Narcolepsy Drug Xyrem - MarketScreener
Amneal receives US FDA approval of Sodium Oxybate Oral Solution - MarketScreener
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution - GlobeNewswire
150,000 Narcolepsy Patients Get New Option: Amneal's FDA-Approved Generic Breaks Single-Maker Market - Stock Titan
Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing (AMRX) - Seeking Alpha
Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by Raymond James Financial Inc. - MarketBeat
Northern Trust Corp Reduces Position in AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
684,116 Shares in AMNEAL PHARMACEUTICALS, INC. $AMRX Bought by Cubist Systematic Strategies LLC - MarketBeat
Anti-Parkinson's Drugs Global Markets to 2030 with AbbVie, Amneal Pharmaceuticals, Acadia Pharmaceut - PharmiWeb.com
Anti-Parkinson's Drugs Global Markets to 2030 with AbbVie, Amneal Pharmaceuticals, Acadia Pharmaceuticals, Supernus Pharmaceuticals and Teva Pharmaceutical DominatingResearchAndMarkets.com - Business Wire
Amneal Pharmaceuticals stock hits 52-week high at $9.79 By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals stock hits 52-week high at $9.79 - Investing.com
Is Amneal Pharmaceuticals Inc. a strong growth stockJuly 2025 Analyst Calls & Community Shared Stock Ideas - beatles.ru
AMNEAL PHARMACEUTICALS, INC. $AMRX Shares Bought by Dark Forest Capital Management LP - MarketBeat
Is Amneal Pharmaceuticals Inc.’s ROE strong enough2025 Analyst Calls & Free Real-Time Volume Trigger Notifications - beatles.ru
Should you wait for a breakout in Amneal Pharmaceuticals Inc.Bear Alert & Fast Moving Stock Trade Plans - Newser
Can machine learning forecast Amneal Pharmaceuticals Inc. recoveryPortfolio Value Summary & Stock Portfolio Risk Management - Newser
Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by Nantahala Capital Management LLC - MarketBeat
FDA Warns Amneal Pharmaceuticals Over Use of Contaminated IV Bags in Sterile Injectable Drug Production - geneonline.com
Amneal gets FDA nod for generic version of Risperdal Consta - MSN
Does Amneal Pharmaceuticals Inc. have pricing powerDollar Strength & Weekly Stock Breakout Alerts - خودرو بانک
Trexquant Investment LP Acquires 167,631 Shares of AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
Should you avoid Amneal Pharmaceuticals Inc. stock right nowJuly 2025 Action & Low Risk Profit Maximizing Plans - خودرو بانک
Using R and stats models for Amneal Pharmaceuticals Inc. forecastingEarnings Risk Report & Advanced Technical Signal Analysis - Newser
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):